An experimental mRNA vaccine has shown promise in a landmark clinical trial for melanoma, the deadliest form of skin cancer. The personalized vaccine, developed by Moderna and Merck, reduced the risk of recurrence or death in patients with high-risk melanoma after surgery. This represents a significant step forward in applying mRNA technology to cancer treatment.

  • The vaccine is tailored to each patient’s unique tumor mutations.
  • Combined with the immunotherapy drug Keytruda, it significantly lowered the rate of melanoma recurrence.
  • Trial results were published in a major medical journal and presented at a cancer conference.
  • A larger phase 3 study is already under way to confirm these findings.

What Is the Experimental mRNA Melanoma Vaccine?

The vaccine, known as mRNA-4157 (V940), is a personalized cancer treatment. It uses messenger RNA to instruct the patient’s immune system to recognize and attack specific mutations found in their melanoma tumor. According to the original news report from KTVU, the vaccine is designed to be used after surgery to prevent the cancer from coming back.

Each dose is custom made for the individual, encoding up to 34 different neoantigens (mutated proteins unique to the patient’s cancer). This approach aims to train the immune system to target only the cancer cells, potentially sparing healthy tissue.

How Does the Vaccine Work?

After a patient’s tumor is removed, scientists sequence its DNA to identify mutations. They then design a synthetic mRNA that carries the genetic instructions for those specific neoantigens. When injected, the mRNA enters immune cells, which display the neoantigens on their surface. This triggers a powerful T cell response against any remaining melanoma cells that carry those mutations.

In the trial, the vaccine was given alongside Keytruda (pembrolizumab), an immunotherapy that blocks the PD-1 pathway. The combination aims to both activate new immune cells and remove the brakes on existing ones, creating a more robust anti cancer immune response.

Key Trial Results

The phase 2b trial enrolled patients with high risk melanoma who had already undergone surgery. Half received the vaccine plus Keytruda, while the other half received Keytruda alone. After a median follow up of about two years, the group that got the vaccine had a significantly lower risk of disease recurrence or death. The original report noted that the reduction in risk was substantial, with the vaccine combination showing a clear advantage over the standard immunotherapy alone.

Researchers also reported that the side effects were manageable. The most common adverse events included fatigue, injection site reactions, and chills. Serious side effects were rare and similar between the two groups.

What Is Next for the Vaccine?

Based on these encouraging results, Moderna and Merck have launched a phase 3 trial that will enroll thousands of patients across multiple countries. If the larger study confirms the benefits, the vaccine could become a new standard of care for high risk melanoma. The companies also plan to test the technology in other cancers, including lung and colorectal tumors.

Regulatory discussions are ongoing. The U.S. Food and Drug Administration has granted breakthrough therapy designation to the vaccine, which may speed up its review process. However, it is not yet approved for routine use.

Frequently Asked Questions

Is the mRNA melanoma vaccine approved?

No, the vaccine is not yet approved by the FDA or other regulatory agencies. It is still investigational, meaning it can only be used in clinical trials. The phase 2b results are promising, but phase 3 data are needed before seeking approval.

Who is eligible for this vaccine?

Currently, the vaccine is only available to participants in clinical trials. In the reported phase 2b study, eligibility was limited to adults with surgically removed stage III or IV melanoma who were at high risk of recurrence. Patients must have sufficient tumor tissue for DNA sequencing and be in generally good health.

What are the side effects of the mRNA melanoma vaccine?

In the trial, common side effects included fatigue, injection site pain, fever, chills, and muscle aches. These are similar to those seen with other vaccines. Serious side effects were uncommon and comparable to the Keytruda alone group. As with any immunotherapy, there is a risk of autoimmune reactions, but the study found no new safety signals.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.